Literature DB >> 26699483

Mesenchymal stem/stromal cells precondition lung monocytes/macrophages to produce tolerance against allo- and autoimmunity in the eye.

Jung Hwa Ko1, Hyun Ju Lee1, Hyun Jeong Jeong1, Mee Kum Kim1, Won Ryang Wee1, Sun-Ok Yoon2, Hosoon Choi3, Darwin J Prockop4, Joo Youn Oh5.   

Abstract

Intravenously administered mesenchymal stem/stromal cells (MSCs) engraft only transiently in recipients, but confer long-term therapeutic benefits in patients with immune disorders. This suggests that MSCs induce immune tolerance by long-lasting effects on the recipient immune regulatory system. Here, we demonstrate that i.v. infusion of MSCs preconditioned lung monocytes/macrophages toward an immune regulatory phenotype in a TNF-α-stimulated gene/protein (TSG)-6-dependent manner. As a result, mice were protected against subsequent immune challenge in two models of allo- and autoimmune ocular inflammation: corneal allotransplantation and experimental autoimmune uveitis (EAU). The monocytes/macrophages primed by MSCs expressed high levels of MHC class II, B220, CD11b, and IL-10, and exhibited T-cell-suppressive activities independently of FoxP3(+) regulatory T cells. Adoptive transfer of MSC-induced B220(+)CD11b(+) monocytes/macrophages prevented corneal allograft rejection and EAU. Deletion of monocytes/macrophages abrogated the MSC-induced tolerance. However, MSCs with TSG-6 knockdown did not induce MHC II(+)B220(+)CD11b(+) cells, and failed to attenuate EAU. Therefore, the results demonstrate a mechanism of the MSC-mediated immune modulation through induction of innate immune tolerance that involves monocytes/macrophages.

Entities:  

Keywords:  corneal allotransplantation; experimental autoimmune uveitis; immune tolerance; mesenchymal stem/stromal cell; monocyte/macrophage

Mesh:

Substances:

Year:  2015        PMID: 26699483      PMCID: PMC4711840          DOI: 10.1073/pnas.1522905113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells.

Authors:  Margaret E Groh; Basabi Maitra; Emese Szekely; Omer N Koç
Journal:  Exp Hematol       Date:  2005-08       Impact factor: 3.084

2.  Gene-specific control of inflammation by TLR-induced chromatin modifications.

Authors:  Simmie L Foster; Diana C Hargreaves; Ruslan Medzhitov
Journal:  Nature       Date:  2007-05-30       Impact factor: 49.962

Review 3.  Endotoxin tolerance: new mechanisms, molecules and clinical significance.

Authors:  Subhra K Biswas; Eduardo Lopez-Collazo
Journal:  Trends Immunol       Date:  2009-09-24       Impact factor: 16.687

4.  Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis.

Authors:  Kentaro Akiyama; Chider Chen; DanDan Wang; Xingtian Xu; Cunye Qu; Takayoshi Yamaza; Tao Cai; WanJun Chen; Lingyun Sun; Songtao Shi
Journal:  Cell Stem Cell       Date:  2012-04-26       Impact factor: 24.633

5.  Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells.

Authors:  K English; J M Ryan; L Tobin; M J Murphy; F P Barry; B P Mahon
Journal:  Clin Exp Immunol       Date:  2009-02-03       Impact factor: 4.330

6.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.

Authors:  Ryang Hwa Lee; Andrey A Pulin; Min Jeong Seo; Daniel J Kota; Joni Ylostalo; Benjamin L Larson; Laura Semprun-Prieto; Patrice Delafontaine; Darwin J Prockop
Journal:  Cell Stem Cell       Date:  2009-07-02       Impact factor: 24.633

7.  Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.

Authors:  Krisztián Németh; Asada Leelahavanichkul; Peter S T Yuen; Balázs Mayer; Alissa Parmelee; Kent Doi; Pamela G Robey; Kantima Leelahavanichkul; Beverly H Koller; Jared M Brown; Xuzhen Hu; Ivett Jelinek; Robert A Star; Eva Mezey
Journal:  Nat Med       Date:  2008-11-21       Impact factor: 53.440

8.  Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation.

Authors:  Fuad S Shihab; William M Bennett; Takeshi F Andoh
Journal:  Transplantation       Date:  2009-02-15       Impact factor: 4.939

Review 9.  Experimental autoimmune uveoretinitis in the rat and mouse.

Authors:  Rachel R Caspi
Journal:  Curr Protoc Immunol       Date:  2003-05

10.  Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Authors:  Katarina Le Blanc; Francesco Frassoni; Lynne Ball; Franco Locatelli; Helene Roelofs; Ian Lewis; Edoardo Lanino; Berit Sundberg; Maria Ester Bernardo; Mats Remberger; Giorgio Dini; R Maarten Egeler; Andrea Bacigalupo; Willem Fibbe; Olle Ringdén
Journal:  Lancet       Date:  2008-05-10       Impact factor: 79.321

View more
  63 in total

Review 1.  Current understanding of the immunosuppressive properties of mesenchymal stromal cells.

Authors:  Ligia Lins de Castro; Miquéias Lopes-Pacheco; Daniel Jay Weiss; Fernanda Ferreira Cruz; Patricia Rieken Macêdo Rocco
Journal:  J Mol Med (Berl)       Date:  2019-03-22       Impact factor: 4.599

Review 2.  The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents?

Authors:  F Carty; B P Mahon; K English
Journal:  Clin Exp Immunol       Date:  2017-02-20       Impact factor: 4.330

3.  Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach.

Authors:  Raghavan Chinnadurai; Devi Rajan; Muna Qayed; Dalia Arafat; Marco Garcia; Yifei Liu; Subra Kugathasan; Larry J Anderson; Greg Gibson; Jacques Galipeau
Journal:  Cell Rep       Date:  2018-02-27       Impact factor: 9.423

4.  Macrophage Subpopulation Dynamics Shift following Intravenous Infusion of Mesenchymal Stromal Cells.

Authors:  Nina Kosaric; Waracharee Srifa; Clark A Bonham; Harriet Kiwanuka; Kellen Chen; Britta A Kuehlmann; Zeshaan N Maan; Chikage Noishiki; Matthew H Porteus; Michael T Longaker; Geoffrey C Gurtner
Journal:  Mol Ther       Date:  2020-05-30       Impact factor: 11.454

5.  Comprehensive Molecular Profiles of Functionally Effective MSC-Derived Extracellular Vesicles in Immunomodulation.

Authors:  Hyemee Kim; Min Joung Lee; Eun-Hye Bae; Jin Suk Ryu; Gagandeep Kaur; Hyeon Ji Kim; Jun Yeob Kim; Heather Barreda; Sung Youn Jung; Jong Min Choi; Taeko Shigemoto-Kuroda; Joo Youn Oh; Ryang Hwa Lee
Journal:  Mol Ther       Date:  2020-04-23       Impact factor: 11.454

Review 6.  The exciting prospects of new therapies with mesenchymal stromal cells.

Authors:  Darwin J Prockop
Journal:  Cytotherapy       Date:  2016-10-18       Impact factor: 5.414

Review 7.  Data against a Common Assumption: Xenogeneic Mouse Models Can Be Used to Assay Suppression of Immunity by Human MSCs.

Authors:  Darwin J Prockop; Joo Youn Oh; Ryang Hwa Lee
Journal:  Mol Ther       Date:  2017-06-22       Impact factor: 11.454

8.  Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing.

Authors:  Raghavan Chinnadurai; Ian B Copland; Marco A Garcia; Christopher T Petersen; Christopher N Lewis; Edmund K Waller; Allan D Kirk; Jacques Galipeau
Journal:  Stem Cells       Date:  2016-07-04       Impact factor: 6.277

9.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review.

Authors:  Alessander Leyendecker; Carla Cristina Gomes Pinheiro; Mariane Tami Amano; Daniela Franco Bueno
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

10.  Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function.

Authors:  Medi Eslani; Ilham Putra; Xiang Shen; Judy Hamouie; Asha Tadepalli; Khandaker N Anwar; John A Kink; Samaneh Ghassemi; Gaurav Agnihotri; Sofiya Reshetylo; Alireza Mashaghi; Reza Dana; Peiman Hematti; Ali R Djalilian
Journal:  Stem Cells       Date:  2018-01-27       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.